falsefalse

Optimizing Early-Stage NSCLC Management Through Multidisciplinary Strategies: ASCO 2025 - Episode 1

Resectable Early-Stage NSCLC: How the Standard of Care Is Evolving

, , , ,

Panelists discuss how the standard of care for resectable early-stage non–small cell lung cancer (NSCLC) has evolved from adjuvant chemotherapy alone to neoadjuvant chemoimmunotherapy and perioperative approaches that combine preoperative treatment with continued immunotherapy after surgery.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    The treatment landscape for resectable early-stage NSCLC has undergone revolutionary changes in recent years, primarily driven by the integration of immunotherapy into standard care protocols. This multidisciplinary panel discussion, featuring leading oncologists from The University of Texas MD Anderson Cancer Center, MedStar Georgetown University Hospital, Tennessee Oncology, University of Chicago Medicine, and Montefiore Einstein Comprehensive Cancer Center, explores the evolving paradigms in early-stage NSCLC management following key updates from the 2025 American Society of Clinical Oncology Annual Meeting.

    The most significant advancement in resectable NSCLC treatment has been the introduction of neoadjuvant chemoimmunotherapy, fundamentally changing patient outcomes for stage IB to III disease. The CheckMate 816 trial initially established neoadjuvant nivolumab plus chemotherapy as a new standard, demonstrating significant improvements in event-free survival and pathologic complete response rates. This breakthrough has since evolved into comprehensive perioperative strategies that combine neoadjuvant chemoimmunotherapy with adjuvant immunotherapy maintenance.

    Modern treatment approaches now encompass 3 approved perioperative chemoimmunotherapy regimens, allowing oncologists to tailor therapy based on individual patient factors, including tumor characteristics, anatomical considerations, and patient preferences. The evolution from purely neoadjuvant approaches to perioperative strategies represents a paradigm shift toward maximizing immunotherapy exposure throughout the surgical treatment continuum, ultimately improving long-term survival outcomes for patients with resectable early-stage NSCLC.

    x